JNJJNJHealthcare · Drug Manufacturers - General

JNJ Stock Forecast: Johnson & Johnson Price Predictions for 2026-2027

Last close, 20 Nov 2026
$271
+1.33% on the day

The 23 Wall Street analysts covering Johnson & Johnson hold a median 12-month price target of $281 — +3.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 86 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$643.1B
Ticker Nerd rank
86/ 100
Median analyst target
$281
Analysts covering
23
Revenue$25.3B+6.6% y/y
Operating income$7.2B
Net income$5.5B
Free cash flow$7.3B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.3%
1M
+4.4%
YTD
+32.9%
1Y
+36.3%
From 52W high
−5.3%
From 52W low
+37.5%
$197
$286
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Johnson & Johnson on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
86/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Momentum
97
Quality
92
Value
89
Issuance
79
Accruals
59
Growth
55
Revisions
48

Volatility (100): The share price has been relatively steady.

Revisions (48): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

JNJ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JNJ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Jan 26Apr 26Jul 26Oct 26JNJHigh $320Median $281Low $190

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
16
Buy
5
Hold
2
Sell
$190
Low
$281
Median
$320
High

The green dot is the last close — the median target sits +3.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 13 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
16 Oct 2026Wells FargoMaintainsOverweight$275 → $287
15 Oct 2026Morgan StanleyMaintainsOverweight$294 → $292
14 Oct 2026Leerink PartnersMaintainsOutperform$276 → $272
14 Oct 2026RBC CapitalMaintainsOutperform$290 → $280
14 Oct 2026Wells FargoMaintainsOverweight$282 → $275
7 Oct 2026GuggenheimReiteratesBuy$287
6 Oct 2026RBC CapitalMaintainsOutperform$287 → $290
5 Oct 2026CitigroupMaintainsBuy$298 → $303
29 Sept 2026JP MorganMaintainsNeutral$270 → $285
10 Sept 2026HSBCMaintainsBuy$290 → $320
2 Sept 2026UBSMaintainsBuy$280 → $320
6 Aug 2026GuggenheimMaintainsBuy$270 → $287
3 Aug 2026Wells FargoMaintainsOverweight$272 → $282
17 July 2026GuggenheimReiteratesBuy$270
16 July 2026Morgan StanleyMaintainsOverweight$284 → $294
16 July 2026Raymond JamesMaintainsOutperform$258 → $265
16 July 2026RBC CapitalReiteratesOutperform$287
16 July 2026Wells FargoMaintainsOverweight$263 → $272
13 July 2026RBC CapitalMaintainsOutperform$265 → $287
13 July 2026TD CowenMaintainsBuy$250 → $300

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for JNJ.

Market Radar

This page is one stock. Monday covers all of them.

JNJ appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

JNJ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Johnson & Johnson returned +36.3% against +6.9% for the S&P 500, dividends included.

JNJ vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140150Jan 26Apr 26Jul 26Oct 26JNJS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JNJ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+0.6%
Analysts raising
6
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
41.3×

Cheaper than 20% of US stocks

Price / sales
6.6×

Cheaper than 16% of US stocks

Price / book
8.0×

Cheaper than 10% of US stocks

EV / EBITDA
19.4×

Cheaper than 22% of US stocks

Growth & margins
Revenue growth (YoY)
5.9%

Higher than 43% of US stocks

Earnings growth (YoY)
−95.9%

Higher than 3% of US stocks

Gross margin
68.2%

Higher than 81% of US stocks

Operating margin
26.6%

Higher than 85% of US stocks

Net margin
—
Returns & dividend
Return on equity
20.0%

Higher than 81% of US stocks

Return on assets
8.5%

Higher than 89% of US stocks

Dividend yield
2.0%

Higher than 42% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Johnson & Johnson has a market value of $643.1B and an enterprise value of $670.5B.

  • Revenue in the twelve months to 30 June 2026: $97.9B. The latest quarter grew 6.6% year on year.

  • Net income over the same four quarters: $21.0B, a 21.5% net margin.

  • Diluted earnings per share, trailing twelve months: $8.63.

  • Free cash flow in the twelve months to 30 June 2026: $22.2B, after $5.4B of capital spending.

  • Johnson & Johnson spent $8.1B on share buybacks and $12.6B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 2.4B.

  • Trailing P/E: 41.3×; forward P/E: 23.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.98%, paying out 80% of earnings.

  • Johnson & Johnson employs 138,200 people — $709K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

JNJ and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
JNJJohnson & Johnson$643.1B86
ABBVAbbVie, Inc.$505.7B90
LLYEli Lilly & Co.$1.3T92
MRKMerck & Co., Inc.$331.9B86
AMGNAmgen, Inc.$234.8B95
GILDGilead Sciences, Inc.$206.6B89
PFEPfizer Inc.$155.8B91

Take a look at JNJ’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Johnson & Johnson — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about JNJ

What is the JNJ stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Johnson & Johnson have a median 12-month price target of $281, with estimates ranging from $190 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JNJ stock a buy right now?

Of the 23 analysts covering Johnson & Johnson, 16 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Johnson & Johnson 86 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JNJ?

As at 21 Nov 2026, Johnson & Johnson ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will JNJ stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +3.6% from the last close, and Ticker Nerd's factor model ranks Johnson & Johnson 86 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JNJ stock forecast for 2030?

No analyst covering Johnson & Johnson publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JNJ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $190 to $320 over the next 12 months.

How has JNJ stock performed over the past year?

Johnson & Johnson returned +36.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Johnson & Johnson do?

Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular care, while its MedTech segment provides medical devices and solutions used in surgery, orthopedics, interventional procedures, and vision care.

Company

About Johnson & Johnson.

Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular care, while its MedTech segment provides medical devices and solutions used in surgery, orthopedics, interventional procedures, and vision care. The company serves hospitals, clinicians, patients, and healthcare systems in markets around the world, making it a central participant in both drug development and medical device supply chains. Johnson & Johnson is known for operating at the intersection of large-scale research, clinical innovation, and essential healthcare delivery, with products that support prevention, treatment, diagnosis, and recovery across a wide range of medical settings.

CEO Mr. Joaquin Duato · 138,200 employees · United States · https://www.jnj.com